Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dipyridamole versus adenosine for FFR assessment of intermediate coronary stenoses
2010-024485-21Phase 3Completed
- Sponsor
- Fondazione Toscana Gabriele Monasterio
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dipyridamole and adenosine in coronary arteriosclerosis and coronary stenosis (2 arms), sponsored by Fondazione Toscana Gabriele Monasterio. Primary endpoint: Non-inferior diagnostic accuracy of dipyridamole-induced FFR versus adenosine-induced FFR. Started Jan 2013; status: completed.
02
Drugs
dipyridamoleadenosine
03
Conditions
coronary arteriosclerosiscoronary stenosis
Beyond the preview
Go deeper on 2010-024485-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024485-21.